Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neoplasms 5Triple Negative Breast Neoplasms 4Breast Neoplasms 4Recurrence 2Ovarian Neoplasms 2Hypersensitivity 2Squamous Cell Lung Cancer 1Solid Tumors 1Neoplasm Metastasis 1Glioblastoma 1Fanconi Anemia, Complementation Group D1 1Carcinoma, Non-Small-Cell Lung 1Breast Cancer Female 1Brain Neoplasms 1Advanced Solid Tumors 1Advance Solid Tumors 1

Interventions

durvalumab 7Carboplatin 7Docetaxel 6Paclitaxel 5Nivolumab 5talazoparib 4linifanib 4Cisplatin 4trifluridine tipiracil drug combination 3tremelimumab 3tislelizumab 3depatuxizumab 3ST 1481 3S 1 (combination) 3Panobinostat 3Gemcitabine 3zimberelimab 2toripalimab 2olaparib 2motesanib diphosphate 2mogamulizumab 2TAS-114 2Sorafenib 2Rifampin 2PM 01183 2Oxaliplatin 2MLN 8237 2Itraconazole 2Injections 2Erlotinib Hydrochloride 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Advanced Solid Tumors × iniparib × Clear all
NCT01161836 2013-09-24

An Open-label Study Investigating the Disposition and QT/QTc Interval Effects of 400 mg [14C]-Iniparib(3.7 MBq, 100 µCi)

Sanofi

Phase 1 Completed
7 enrolled
Other solid neoplasm

Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡